Jim Cramer expects to see more deal activity in the pharmaceuticals space.
Never mind the Ohio health care services company's better-than-anticipated Q3 earnings.
Jim Cramer believes the pharmaceutical sector has come full circle and some of the best stocks in the group are ready to move higher.
Jim Cramer is bullish on Abbott Laboratories' acquisition of St. Jude Medical.
The maker of scientific instruments hiked full-year expectations in light of its $1.3 billion deal for Affymetrix.
Senior FDA officials, most notably Dr. Janet Woodcock, the agency's top drug evaluator, spent a lot of time at Monday's panel making supportive statements about eteplirsen.
U.S. stocks dropped on Thursday, as first quarter gross domestic product came in weaker than expected.
By Bruce Kamich
There are mixed sigs in the charts.
By Dick Arms
Movement has become difficult after weeks of advances, which suggests a downturn may be near.
Vertex Pharmaceuticals tried to soothe fears about the commercial ramp of its cystic fibrosis franchise by providing Orkambi sales guidance for the first time since the drug launched last summer.
General Electric share owners ratified 2015 compensation for executives including CEO Jeffrey Immelt and elected the company's slate of directors with a two-thirds majority on Wednesday.
The health insurance giant doesn't plan to add to or exit any of its 14 Obamacare exchanges, though that could change if its $54.2 billion acquisition of Cigna is completed.
By Bruce Kamich
The rate of decline slowed into the base, just what chartists like to see.
MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.
New products such as Trulicity, Cyramza, Jardiance, Basaglar and Portrazza fueled the drugmaker's revenue growth in the first quarter.
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.